---
schema_version: "secwatch.filing_event.v1"
accession: "0001641489-23-000068"
form_type: "8-K"
ticker: "VTVT"
cik: "0001641489"
company_name: "vTv Therapeutics Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:50:21.895202+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# vTv Therapeutics Q3 net loss widens to $6.7M; cash drops to $8.2M

## Summary
- Net loss of $6.7M ($0.08 per share) vs $4.3M ($0.05) in Q3 2022.
- Cash and equivalents fell to $8.2M from $12.1M at Dec. 31, 2022.
- R&D expenses were $2.8M, down from $3.1M YoY on lower cadisegliatin costs.
- Appointed Dr. Thomas Strack as Chief Medical Officer on November 2, 2023.
- Received $4.4M from Reneo for repurchase of Reneo common stock on Nov 1, 2023.

## SEC filing metadata
- accession: 0001641489-23-000068
- form_type: 8-K
- ticker: VTVT
- cik: 0001641489
- company_name: vTv Therapeutics Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641489/000164148923000068/0001641489-23-000068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641489/000164148923000068/vtvt-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641489-23-000068
- JSON: https://secwatch.observer/filing/0001641489-23-000068.json
- Plain text: https://secwatch.observer/filing/0001641489-23-000068.txt

## Key facts
- Earnings Releases
  vTv Therapeutics Inc. reported third quarter ended September 30, 2023 results: revenue $ —, net income $6.7 million, EPS $0.08 per basic share.
  - Period: third quarter ended September 30, 2023
  - Revenue: $ —
  - Net income: $6.7 million
  - EPS: $0.08 per basic share
  - Result: reported results
  source text: Net loss attributable to vTv shareholders for the three months ended September 30, 2023, was $6.7 million or $0.08 per basic share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641489/000164148923000068/0001641489-23-000068-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.